Form 4: Verrica Pharmaceuticals Executive Acquires Shares and Stock Options
SEC Form 4
Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals, reports acquisition of shares and stock options.
Summary
- On March 15, 2024, Joe Bonaccorso, the Chief Commercial Officer of Verrica Pharmaceuticals, acquired 40,000 shares of common stock and 80,000 employee stock options.
- The common stock was acquired at a price of $0.
- Following the transaction, Bonaccorso directly owns 132,392 shares of common stock.
- The stock options have an exercise price of $4.80 and expire on March 15, 2034.
- The options vest 25% on March 15, 2025, and then 1/48th monthly over the remaining three years.
- The restricted stock units (RSUs) vest in equal annual installments on March 15, 2025, March 15, 2026, March 15, 2027 and March 15, 2028.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares could be interpreted slightly positively, but it's primarily an informational document.
Positives
- The acquisition of shares and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure related to executive compensation and ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/15/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/15/2025 | First vesting date for both RSUs and 25% of stock options. |
| 03/15/2026 | Second vesting date for RSUs. |
| 03/15/2027 | Third vesting date for RSUs. |
| 03/15/2028 | Final vesting date for RSUs. |
| 03/15/2034 | Expiration date for the employee stock options. |
| 03/19/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.